Healthcare

Continuous Manufacturing (CM) for Oral Solid Dosage Form

Continuous manufacturing (CM) is nowadays considered as a key option for optimizing production processes in the pharmaceutical industry.

Infographic Continuous manufacturing

The main advantages of the continuous manufacturing (CM) over the batch manufacturing leading to cost savings and quality optimization are as follow:

  • fewer processing steps
  • reduced equipment size
  • rapid development and easy scale-up
  • improved quality due to utilization of process analytical technologies
  • quality optimization
  • possible costs savings

In contrary to the conventional batch process, the first step in CM is powder feeding instead of  powder blending. Hence, it is essential to optimize the powder flow behavior and the physicochemical properties of each material to maximize the feeding step.

 
Filter applications by:

    Wet granulation (WG) immediate release (IR)

    In wet granulation processes, the fluid bed and high shear granulator, known as typical batch processes, are getting designed by manufacturers to be transferred into continuous manufacturing. Nowadays, the twin screw granulation, in which powders and liquids can be fed in a continuous way, are seen as a promising wet granulation technique to be implemented in a CM line. Besides the use of low viscosity hypromellose as binder: PHARMACOAT® or TYLOPUR®, the addition of multi-functional excipients, like L-HPC (low substituted hydroxypropylcellulose) can simplify the formulation.

    Recommended products

    GradesDescriptionPharmacopoeiaOriginRecommendationKnowledge Base
    PHARMACOAT® 603 Hypromellose 2910, 3 mPasUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    LAB Poster Tablet defects
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    PHARMACOAT® 645 Hypromellose 2910, 4.5 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    PHARMACOAT® 606 Hypromellose 2910, 6 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    LAB Poster Tablet defects
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Solubility of PHARMACOAT® 606 in acetone/water mixtures [P-016]
    Solubility of PHARMACOAT® 606 in alcohol-water mixtures [P-004]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    PHARMACOAT® 615 Hypromellose 2910, 15 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    L-HPC LH-11 50 µm, 11 % HPONF, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    LAB Poster Tablet defects
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Change of swelling performance of disintegrants after wet granulation [L-031]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
    Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
    Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
    Influence of tablet shape on capping tendency [L-032]
    Interaction with L-HPC and vitamins [L-038]
    Minitablets using L-HPC [L-024]
    Pellet extrusion - spheronizazion using L-HPC [L-011]
    Pellets preparation by drug layering using L-HPC [L-015]
    Rapid release from hard capsules using L-HPC as a filler [L-009]
    Roller compaction using L-HPC - influence of re-processing [L-010]
    Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
    The effect of a glidant on L-HPC [L-029]
    The effect of a glidant on L-HPC for dry granulation [L-030]
    Twin screw granulation using L-HPC [L-028]
    Water absorption of L-HPC [L-041]
    Water binding capability of L-HPC in wet granulation [L-018]
    L-HPC LH-21. 22 45 µm, 8-11 % HPONF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Change of swelling performance of disintegrants after wet granulation [L-031]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
    Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
    Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
    Influence of tablet shape on capping tendency [L-032]
    Interaction with L-HPC and vitamins [L-038]
    Minitablets using L-HPC [L-024]
    Pellet extrusion - spheronizazion using L-HPC [L-011]
    Pellets preparation by drug layering using L-HPC [L-015]
    Rapid release from hard capsules using L-HPC as a filler [L-009]
    Roller compaction using L-HPC - influence of re-processing [L-010]
    Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
    The effect of a glidant on L-HPC [L-029]
    The effect of a glidant on L-HPC for dry granulation [L-030]
    Twin screw granulation using L-HPC [L-028]
    Water absorption of L-HPC [L-041]
    Water binding capability of L-HPC in wet granulation [L-018]
    L-HPC LH-B1 50 µm, 11 % HPONF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Change of swelling performance of disintegrants after wet granulation [L-031]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
    Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
    Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
    Influence of tablet shape on capping tendency [L-032]
    Interaction with L-HPC and vitamins [L-038]
    Minitablets using L-HPC [L-024]
    Pellet extrusion - spheronizazion using L-HPC [L-011]
    Pellets preparation by drug layering using L-HPC [L-015]
    Rapid release from hard capsules using L-HPC as a filler [L-009]
    Roller compaction using L-HPC - influence of re-processing [L-010]
    Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
    The effect of a glidant on L-HPC [L-029]
    The effect of a glidant on L-HPC for dry granulation [L-030]
    Twin screw granulation using L-HPC [L-028]
    Water absorption of L-HPC [L-041]
    Water binding capability of L-HPC in wet granulation [L-018]
    L-HPC LH-31. 32 20 µm, 8-11 % HPONF, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Change of swelling performance of disintegrants after wet granulation [L-031]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
    Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
    Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
    Influence of tablet shape on capping tendency [L-032]
    Interaction with L-HPC and vitamins [L-038]
    Minitablets using L-HPC [L-024]
    Pellet extrusion - spheronizazion using L-HPC [L-011]
    Pellets preparation by drug layering using L-HPC [L-015]
    Rapid release from hard capsules using L-HPC as a filler [L-009]
    Roller compaction using L-HPC - influence of re-processing [L-010]
    Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
    The effect of a glidant on L-HPC [L-029]
    The effect of a glidant on L-HPC for dry granulation [L-030]
    Twin screw granulation using L-HPC [L-028]
    Water absorption of L-HPC [L-041]
    Water binding capability of L-HPC in wet granulation [L-018]
    L-HPC NBD-020 45 µm, 14 % HPONF, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
    Super-high speed direct compression using L-HPC NBD [L-027]
    L-HPC NBD-021 45 µm, 11 % HPONF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
    Super-high speed direct compression using L-HPC NBD [L-027]
    L-HPC NBD-022 45 µm, 8 % HPONF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
    Super-high speed direct compression using L-HPC NBD [L-027]
    TYLOPUR® 603 Hypromellose 2910, 3 mPasUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 603
    TYLOPUR® 645 Hypromellose 2910, 4.5 mPasUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 645
    TYLOPUR® 605 Hypromellose 2910, 5 mPasUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 605
    TYLOPUR® 606 Hypromellose 2910, 6 mPasUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 606
    TYLOPUR® 615 Hypromellose 2910, 15 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 615

    Wet granulation (WG) sustained release (SR)

    Wet granulation processes are generally used to improve flowability and homogeneity of powders. For the high shear granulation, the appropriate selection of organic solvent/ water ratio and the granulation time are key parameters to guaranty a good compactibility and steady dissolution profile of matrix tablets based on METOLOSE®/ TYLOPUR® SR (HPMC) (see technical information SR-003).

    One advantage of using the twin screw granulation over other traditional wet granulation techniques is, besides being a more straight forward continuous process, the possibility of using only water. Indeed, shorter granulation time resulting in lower hydration of the HPMC allows to obtain similar granules properties and steady dissolution profiles compared to standard high shear granulation.

    Recommended products

    GradesDescriptionPharmacopoeiaOriginRecommendationKnowledge Base
    METOLOSE® 60SH´s Hypromellose 2910, different viscosities 50-10000 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Dissolution behavior of various lower viscosity grades [P-014]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grades cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Solubility of HPMC and MC in organic solvents [M-004]
    Taste masking for fine granules by METOLOSE® and an acrylic polymer [M-003]
    METOLOSE® 65SH´s Hypromellose 2906, different viscosities 50-4000 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Dissolution behavior of various lower viscosity grades [P-014]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grades cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Solubility of HPMC and MC in organic solvents [M-004]
    Taste masking for fine granules by METOLOSE® and an acrylic polymer [M-003]
    METOLOSE® 90SH´s Hypromellose 2208, different viscosities 4000-100000 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Dissolution behavior of various lower viscosity grades [P-014]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grades cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Solubility of HPMC and MC in organic solvents [M-004]
    Taste masking for fine granules by METOLOSE® and an acrylic polymer [M-003]
    METOLOSE® SR 90SH-100SR Hypromellose 2208, 100 mPas, sustained releaseUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE SR®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A study on the robustness of the wet granulation process to prepare metformin HCL extended-release matrix tablet using METOLOSE® 90SH-15000SR [SR-006]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Coating application of METOLOSE® in extended release pellet formulation [SR-020]
    Coating application of METOLOSE® in sustained release tablets [SR-019]
    Comparative study of dissolutions from matrix tablets with METOLOSE® SR by different preparation methods [SR-012]
    Comparison between direct compression and wet granulation in hydrophilic matrix tablet using METOLOSE® SR [SR-001]
    Formulation of metformin HCl sustained release tablets [SR-018]
    Formulation of paracetamol bilayer tablet (dose: 650 mg) [SR-017]
    Impact of combination of METOLOSE®SR grades in Carbamazepine extended release matrix tablet formulation [SR-021]
    Particle size analysis of METOLOSE® SR with various laser analysers [SR-010]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Acetaminophen) [SR-014]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Metformin) [SR-011]
    QbD (Quality by Design) approach to the formulation of hydrophylic matrix tablets using METOLOSE® SR (Dipyridamole) [SR-009]
    Solvent selection in wet granulation for hydrophilic matrix tablets using METOLOSE® SR [SR-003]
    The effect of CMCNa on the dissolution profiles of hydrophylic matrix tablets containg METOLOSE® SR [SR-008]
    The effect of glidant of hydrophilic matrix tablets containing METOLOSE® SR [SR-015]
    The effect of the solubility of APIs on the dissolution profiles of hydrophylic matrix tablets containing METOLOSE® SR [SR-007]
    METOLOSE® SR 90SH-4000SR Hypromellose 2208, 4000 mPas, sustained releaseUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE SR®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A study on the robustness of the wet granulation process to prepare metformin HCL extended-release matrix tablet using METOLOSE® 90SH-15000SR [SR-006]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Coating application of METOLOSE® in extended release pellet formulation [SR-020]
    Coating application of METOLOSE® in sustained release tablets [SR-019]
    Comparative study of dissolutions from matrix tablets with METOLOSE® SR by different preparation methods [SR-012]
    Comparison between direct compression and wet granulation in hydrophilic matrix tablet using METOLOSE® SR [SR-001]
    Formulation of metformin HCl sustained release tablets [SR-018]
    Formulation of paracetamol bilayer tablet (dose: 650 mg) [SR-017]
    Impact of combination of METOLOSE®SR grades in Carbamazepine extended release matrix tablet formulation [SR-021]
    Particle size analysis of METOLOSE® SR with various laser analysers [SR-010]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Acetaminophen) [SR-014]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Metformin) [SR-011]
    QbD (Quality by Design) approach to the formulation of hydrophylic matrix tablets using METOLOSE® SR (Dipyridamole) [SR-009]
    Solvent selection in wet granulation for hydrophilic matrix tablets using METOLOSE® SR [SR-003]
    The effect of CMCNa on the dissolution profiles of hydrophylic matrix tablets containg METOLOSE® SR [SR-008]
    The effect of glidant of hydrophilic matrix tablets containing METOLOSE® SR [SR-015]
    The effect of the solubility of APIs on the dissolution profiles of hydrophylic matrix tablets containing METOLOSE® SR [SR-007]
    METOLOSE® SR 90SH-15000SR Hypromellose 2208, 15000 mPas, sustained releaseUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE SR®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A study on the robustness of the wet granulation process to prepare metformin HCL extended-release matrix tablet using METOLOSE® 90SH-15000SR [SR-006]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Coating application of METOLOSE® in extended release pellet formulation [SR-020]
    Coating application of METOLOSE® in sustained release tablets [SR-019]
    Comparative study of dissolutions from matrix tablets with METOLOSE® SR by different preparation methods [SR-012]
    Comparison between direct compression and wet granulation in hydrophilic matrix tablet using METOLOSE® SR [SR-001]
    Formulation of metformin HCl sustained release tablets [SR-018]
    Formulation of paracetamol bilayer tablet (dose: 650 mg) [SR-017]
    Impact of combination of METOLOSE®SR grades in Carbamazepine extended release matrix tablet formulation [SR-021]
    Particle size analysis of METOLOSE® SR with various laser analysers [SR-010]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Acetaminophen) [SR-014]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Metformin) [SR-011]
    QbD (Quality by Design) approach to the formulation of hydrophylic matrix tablets using METOLOSE® SR (Dipyridamole) [SR-009]
    Solvent selection in wet granulation for hydrophilic matrix tablets using METOLOSE® SR [SR-003]
    The effect of CMCNa on the dissolution profiles of hydrophylic matrix tablets containg METOLOSE® SR [SR-008]
    The effect of glidant of hydrophilic matrix tablets containing METOLOSE® SR [SR-015]
    The effect of the solubility of APIs on the dissolution profiles of hydrophylic matrix tablets containing METOLOSE® SR [SR-007]
    METOLOSE® SR 90SH-100000SR Hypromellose 2208, 100000 mPas, sustained releaseUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE SR®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A study on the robustness of the wet granulation process to prepare metformin HCL extended-release matrix tablet using METOLOSE® 90SH-15000SR [SR-006]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Coating application of METOLOSE® in extended release pellet formulation [SR-020]
    Coating application of METOLOSE® in sustained release tablets [SR-019]
    Comparative study of dissolutions from matrix tablets with METOLOSE® SR by different preparation methods [SR-012]
    Comparison between direct compression and wet granulation in hydrophilic matrix tablet using METOLOSE® SR [SR-001]
    Formulation of metformin HCl sustained release tablets [SR-018]
    Formulation of paracetamol bilayer tablet (dose: 650 mg) [SR-017]
    Impact of combination of METOLOSE®SR grades in Carbamazepine extended release matrix tablet formulation [SR-021]
    Particle size analysis of METOLOSE® SR with various laser analysers [SR-010]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Acetaminophen) [SR-014]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Metformin) [SR-011]
    QbD (Quality by Design) approach to the formulation of hydrophylic matrix tablets using METOLOSE® SR (Dipyridamole) [SR-009]
    Solvent selection in wet granulation for hydrophilic matrix tablets using METOLOSE® SR [SR-003]
    The effect of CMCNa on the dissolution profiles of hydrophylic matrix tablets containg METOLOSE® SR [SR-008]
    The effect of glidant of hydrophilic matrix tablets containing METOLOSE® SR [SR-015]
    The effect of the solubility of APIs on the dissolution profiles of hydrophylic matrix tablets containing METOLOSE® SR [SR-007]
    TYLOPUR® 60SH-4000 Hypromellose 2910, 4000 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Safety Data Sheets
    Tylopur 60SH-4000
    TYLOPUR® 60SH-13000 Hypromellose 2910, 13000 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Safety Data Sheets
    Tylopur 60SH-10000
    TYLOPUR® SR 90SH-100SR Hypromellose 2208, 100 mPas, sustained releaseUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Safety Data Sheets
    Tylopur 90SH-100SR
    TYLOPUR® SR 90SH-4000SR Hypromellose 2208, 4000 mPas, sustained releaseUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Safety Data Sheets
    Tylopur 90SH-4000SR
    TYLOPUR® SR 90SH-15000SR Hypromellose 2208, 15000 mPas, sustained releaseUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Safety Data Sheets
    Tylopur 90SH-15000SR
    TYLOPUR® SR 90SH-100000SR Hypromellose 2208, 100000 mPas, sustained releaseUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Safety Data Sheets
    Tylopur 90SH-100000SR

    Roller compaction (RC) immediate release (IR)

    Roller compaction is a dry granulation technique that is seen as a continuous process. The powder blend requires sufficient binding to form a stable ribbon and larger granules with less fine powders after the milling step. Powders are feed into the roller compactor thus the flow property and multifunctionality of powders similar to direct compression can be considered as key properties.

    L-HPC NBD grades are low-substituted hydroxypropyl cellulose and increase the binding properties of your roller compaction formulation. At the same time L-HPC acts as disintegrant ensuring the quick disintegration of your roller compacted IR formulation. Best performance in roller compaction is given by the L-HPC NBD grades with optimized particle size distribution and compactibility.

    Recommended products

    GradesDescriptionPharmacopoeiaOriginRecommendationKnowledge Base
    L-HPC LH-11 50 µm, 11 % HPONF, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    LAB Poster Tablet defects
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Change of swelling performance of disintegrants after wet granulation [L-031]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
    Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
    Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
    Influence of tablet shape on capping tendency [L-032]
    Interaction with L-HPC and vitamins [L-038]
    Minitablets using L-HPC [L-024]
    Pellet extrusion - spheronizazion using L-HPC [L-011]
    Pellets preparation by drug layering using L-HPC [L-015]
    Rapid release from hard capsules using L-HPC as a filler [L-009]
    Roller compaction using L-HPC - influence of re-processing [L-010]
    Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
    The effect of a glidant on L-HPC [L-029]
    The effect of a glidant on L-HPC for dry granulation [L-030]
    Twin screw granulation using L-HPC [L-028]
    Water absorption of L-HPC [L-041]
    Water binding capability of L-HPC in wet granulation [L-018]
    L-HPC LH-21. 22 45 µm, 8-11 % HPONF, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Change of swelling performance of disintegrants after wet granulation [L-031]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
    Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
    Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
    Influence of tablet shape on capping tendency [L-032]
    Interaction with L-HPC and vitamins [L-038]
    Minitablets using L-HPC [L-024]
    Pellet extrusion - spheronizazion using L-HPC [L-011]
    Pellets preparation by drug layering using L-HPC [L-015]
    Rapid release from hard capsules using L-HPC as a filler [L-009]
    Roller compaction using L-HPC - influence of re-processing [L-010]
    Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
    The effect of a glidant on L-HPC [L-029]
    The effect of a glidant on L-HPC for dry granulation [L-030]
    Twin screw granulation using L-HPC [L-028]
    Water absorption of L-HPC [L-041]
    Water binding capability of L-HPC in wet granulation [L-018]
    L-HPC LH-B1 50 µm, 11 % HPONF, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Change of swelling performance of disintegrants after wet granulation [L-031]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
    Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
    Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
    Influence of tablet shape on capping tendency [L-032]
    Interaction with L-HPC and vitamins [L-038]
    Minitablets using L-HPC [L-024]
    Pellet extrusion - spheronizazion using L-HPC [L-011]
    Pellets preparation by drug layering using L-HPC [L-015]
    Rapid release from hard capsules using L-HPC as a filler [L-009]
    Roller compaction using L-HPC - influence of re-processing [L-010]
    Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
    The effect of a glidant on L-HPC [L-029]
    The effect of a glidant on L-HPC for dry granulation [L-030]
    Twin screw granulation using L-HPC [L-028]
    Water absorption of L-HPC [L-041]
    Water binding capability of L-HPC in wet granulation [L-018]
    L-HPC LH-31. 32 20 µm, 8-11 % HPONF, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Change of swelling performance of disintegrants after wet granulation [L-031]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
    Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
    Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
    Influence of tablet shape on capping tendency [L-032]
    Interaction with L-HPC and vitamins [L-038]
    Minitablets using L-HPC [L-024]
    Pellet extrusion - spheronizazion using L-HPC [L-011]
    Pellets preparation by drug layering using L-HPC [L-015]
    Rapid release from hard capsules using L-HPC as a filler [L-009]
    Roller compaction using L-HPC - influence of re-processing [L-010]
    Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
    The effect of a glidant on L-HPC [L-029]
    The effect of a glidant on L-HPC for dry granulation [L-030]
    Twin screw granulation using L-HPC [L-028]
    Water absorption of L-HPC [L-041]
    Water binding capability of L-HPC in wet granulation [L-018]
    L-HPC NBD-020 45 µm, 14 % HPONF, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
    Super-high speed direct compression using L-HPC NBD [L-027]
    L-HPC NBD-021 45 µm, 11 % HPONF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
    Super-high speed direct compression using L-HPC NBD [L-027]
    L-HPC NBD-022 45 µm, 8 % HPONF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
    Super-high speed direct compression using L-HPC NBD [L-027]

    Roller compaction (RC) sustained release (SR)

    Roller compaction is a dry granulation technique that is seen as a continuous process. The powder blend requires sufficient binding to form a stable ribbon and larger granules with less fine powders after the milling step. Powders are feed into the roller compactor thus the flow property and multifunctionality of powders similar to direct compression can be considered as key properties.

    Roller compactor can be selected for the preparation of hydrophilic matrix tablets for sustained release formulations. METOLOSE®/ TYLOPUR® SR (HPMC) manifest sufficient flowability to be feed into the roller compactor.

    Recommended products

    GradesDescriptionPharmacopoeiaOriginRecommendationKnowledge Base
    METOLOSE® 60SH´s Hypromellose 2910, different viscosities 50-10000 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Dissolution behavior of various lower viscosity grades [P-014]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grades cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Solubility of HPMC and MC in organic solvents [M-004]
    Taste masking for fine granules by METOLOSE® and an acrylic polymer [M-003]
    METOLOSE® 65SH´s Hypromellose 2906, different viscosities 50-4000 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Dissolution behavior of various lower viscosity grades [P-014]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grades cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Solubility of HPMC and MC in organic solvents [M-004]
    Taste masking for fine granules by METOLOSE® and an acrylic polymer [M-003]
    METOLOSE® 90SH´s Hypromellose 2208, different viscosities 4000-100000 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Dissolution behavior of various lower viscosity grades [P-014]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grades cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Solubility of HPMC and MC in organic solvents [M-004]
    Taste masking for fine granules by METOLOSE® and an acrylic polymer [M-003]
    METOLOSE® SR 90SH-100SR Hypromellose 2208, 100 mPas, sustained releaseUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE SR®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A study on the robustness of the wet granulation process to prepare metformin HCL extended-release matrix tablet using METOLOSE® 90SH-15000SR [SR-006]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Coating application of METOLOSE® in extended release pellet formulation [SR-020]
    Coating application of METOLOSE® in sustained release tablets [SR-019]
    Comparative study of dissolutions from matrix tablets with METOLOSE® SR by different preparation methods [SR-012]
    Comparison between direct compression and wet granulation in hydrophilic matrix tablet using METOLOSE® SR [SR-001]
    Formulation of metformin HCl sustained release tablets [SR-018]
    Formulation of paracetamol bilayer tablet (dose: 650 mg) [SR-017]
    Impact of combination of METOLOSE®SR grades in Carbamazepine extended release matrix tablet formulation [SR-021]
    Particle size analysis of METOLOSE® SR with various laser analysers [SR-010]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Acetaminophen) [SR-014]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Metformin) [SR-011]
    QbD (Quality by Design) approach to the formulation of hydrophylic matrix tablets using METOLOSE® SR (Dipyridamole) [SR-009]
    Solvent selection in wet granulation for hydrophilic matrix tablets using METOLOSE® SR [SR-003]
    The effect of CMCNa on the dissolution profiles of hydrophylic matrix tablets containg METOLOSE® SR [SR-008]
    The effect of glidant of hydrophilic matrix tablets containing METOLOSE® SR [SR-015]
    The effect of the solubility of APIs on the dissolution profiles of hydrophylic matrix tablets containing METOLOSE® SR [SR-007]
    METOLOSE® SR 90SH-4000SR Hypromellose 2208, 4000 mPas, sustained releaseUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE SR®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A study on the robustness of the wet granulation process to prepare metformin HCL extended-release matrix tablet using METOLOSE® 90SH-15000SR [SR-006]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Coating application of METOLOSE® in extended release pellet formulation [SR-020]
    Coating application of METOLOSE® in sustained release tablets [SR-019]
    Comparative study of dissolutions from matrix tablets with METOLOSE® SR by different preparation methods [SR-012]
    Comparison between direct compression and wet granulation in hydrophilic matrix tablet using METOLOSE® SR [SR-001]
    Formulation of metformin HCl sustained release tablets [SR-018]
    Formulation of paracetamol bilayer tablet (dose: 650 mg) [SR-017]
    Impact of combination of METOLOSE®SR grades in Carbamazepine extended release matrix tablet formulation [SR-021]
    Particle size analysis of METOLOSE® SR with various laser analysers [SR-010]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Acetaminophen) [SR-014]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Metformin) [SR-011]
    QbD (Quality by Design) approach to the formulation of hydrophylic matrix tablets using METOLOSE® SR (Dipyridamole) [SR-009]
    Solvent selection in wet granulation for hydrophilic matrix tablets using METOLOSE® SR [SR-003]
    The effect of CMCNa on the dissolution profiles of hydrophylic matrix tablets containg METOLOSE® SR [SR-008]
    The effect of glidant of hydrophilic matrix tablets containing METOLOSE® SR [SR-015]
    The effect of the solubility of APIs on the dissolution profiles of hydrophylic matrix tablets containing METOLOSE® SR [SR-007]
    METOLOSE® SR 90SH-15000SR Hypromellose 2208, 15000 mPas, sustained releaseUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE SR®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A study on the robustness of the wet granulation process to prepare metformin HCL extended-release matrix tablet using METOLOSE® 90SH-15000SR [SR-006]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Coating application of METOLOSE® in extended release pellet formulation [SR-020]
    Coating application of METOLOSE® in sustained release tablets [SR-019]
    Comparative study of dissolutions from matrix tablets with METOLOSE® SR by different preparation methods [SR-012]
    Comparison between direct compression and wet granulation in hydrophilic matrix tablet using METOLOSE® SR [SR-001]
    Formulation of metformin HCl sustained release tablets [SR-018]
    Formulation of paracetamol bilayer tablet (dose: 650 mg) [SR-017]
    Impact of combination of METOLOSE®SR grades in Carbamazepine extended release matrix tablet formulation [SR-021]
    Particle size analysis of METOLOSE® SR with various laser analysers [SR-010]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Acetaminophen) [SR-014]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Metformin) [SR-011]
    QbD (Quality by Design) approach to the formulation of hydrophylic matrix tablets using METOLOSE® SR (Dipyridamole) [SR-009]
    Solvent selection in wet granulation for hydrophilic matrix tablets using METOLOSE® SR [SR-003]
    The effect of CMCNa on the dissolution profiles of hydrophylic matrix tablets containg METOLOSE® SR [SR-008]
    The effect of glidant of hydrophilic matrix tablets containing METOLOSE® SR [SR-015]
    The effect of the solubility of APIs on the dissolution profiles of hydrophylic matrix tablets containing METOLOSE® SR [SR-007]
    METOLOSE® SR 90SH-100000SR Hypromellose 2208, 100000 mPas, sustained releaseUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE SR®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A study on the robustness of the wet granulation process to prepare metformin HCL extended-release matrix tablet using METOLOSE® 90SH-15000SR [SR-006]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Coating application of METOLOSE® in extended release pellet formulation [SR-020]
    Coating application of METOLOSE® in sustained release tablets [SR-019]
    Comparative study of dissolutions from matrix tablets with METOLOSE® SR by different preparation methods [SR-012]
    Comparison between direct compression and wet granulation in hydrophilic matrix tablet using METOLOSE® SR [SR-001]
    Formulation of metformin HCl sustained release tablets [SR-018]
    Formulation of paracetamol bilayer tablet (dose: 650 mg) [SR-017]
    Impact of combination of METOLOSE®SR grades in Carbamazepine extended release matrix tablet formulation [SR-021]
    Particle size analysis of METOLOSE® SR with various laser analysers [SR-010]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Acetaminophen) [SR-014]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Metformin) [SR-011]
    QbD (Quality by Design) approach to the formulation of hydrophylic matrix tablets using METOLOSE® SR (Dipyridamole) [SR-009]
    Solvent selection in wet granulation for hydrophilic matrix tablets using METOLOSE® SR [SR-003]
    The effect of CMCNa on the dissolution profiles of hydrophylic matrix tablets containg METOLOSE® SR [SR-008]
    The effect of glidant of hydrophilic matrix tablets containing METOLOSE® SR [SR-015]
    The effect of the solubility of APIs on the dissolution profiles of hydrophylic matrix tablets containing METOLOSE® SR [SR-007]
    TYLOPUR® 60SH-4000 Hypromellose 2910, 4000 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Safety Data Sheets
    Tylopur 60SH-4000
    TYLOPUR® 60SH-13000 Hypromellose 2910, 13000 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Safety Data Sheets
    Tylopur 60SH-10000
    TYLOPUR® SR 90SH-100SR Hypromellose 2208, 100 mPas, sustained releaseUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Safety Data Sheets
    Tylopur 90SH-100SR
    TYLOPUR® SR 90SH-4000SR Hypromellose 2208, 4000 mPas, sustained releaseUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Safety Data Sheets
    Tylopur 90SH-4000SR
    TYLOPUR® SR 90SH-15000SR Hypromellose 2208, 15000 mPas, sustained releaseUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Safety Data Sheets
    Tylopur 90SH-15000SR
    TYLOPUR® SR 90SH-100000SR Hypromellose 2208, 100000 mPas, sustained releaseUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Safety Data Sheets
    Tylopur 90SH-100000SR

    Direct compression (DC) immediate release (IR)

    Direct compression is the easiest manufacturing process to be implemented as continuous process. Good flowing excipients are key to allow a homogenous feeding. The L-HPC NBD grades have optimized particle shape and particle size distribution designed to maximize the flow property.

    The use of co-processed excipients like SmartEx® Plus with improved powder flow and functionality for direct compression additionally allows the reduction of the feeders in the CM line.

    Recommended products

    GradesDescriptionPharmacopoeiaOriginRecommendationKnowledge Base
    SmartEx® Plus Co-processed excipientNF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    SmartEx®Plus
    Safety Data Sheets
    Safety Data Sheet
    L-HPC LH-11 50 µm, 11 % HPONF, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    LAB Poster Tablet defects
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Change of swelling performance of disintegrants after wet granulation [L-031]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
    Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
    Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
    Influence of tablet shape on capping tendency [L-032]
    Interaction with L-HPC and vitamins [L-038]
    Minitablets using L-HPC [L-024]
    Pellet extrusion - spheronizazion using L-HPC [L-011]
    Pellets preparation by drug layering using L-HPC [L-015]
    Rapid release from hard capsules using L-HPC as a filler [L-009]
    Roller compaction using L-HPC - influence of re-processing [L-010]
    Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
    The effect of a glidant on L-HPC [L-029]
    The effect of a glidant on L-HPC for dry granulation [L-030]
    Twin screw granulation using L-HPC [L-028]
    Water absorption of L-HPC [L-041]
    Water binding capability of L-HPC in wet granulation [L-018]
    L-HPC LH-21. 22 45 µm, 8-11 % HPONF, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Change of swelling performance of disintegrants after wet granulation [L-031]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
    Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
    Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
    Influence of tablet shape on capping tendency [L-032]
    Interaction with L-HPC and vitamins [L-038]
    Minitablets using L-HPC [L-024]
    Pellet extrusion - spheronizazion using L-HPC [L-011]
    Pellets preparation by drug layering using L-HPC [L-015]
    Rapid release from hard capsules using L-HPC as a filler [L-009]
    Roller compaction using L-HPC - influence of re-processing [L-010]
    Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
    The effect of a glidant on L-HPC [L-029]
    The effect of a glidant on L-HPC for dry granulation [L-030]
    Twin screw granulation using L-HPC [L-028]
    Water absorption of L-HPC [L-041]
    Water binding capability of L-HPC in wet granulation [L-018]
    L-HPC LH-B1 50 µm, 11 % HPONF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Change of swelling performance of disintegrants after wet granulation [L-031]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
    Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
    Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
    Influence of tablet shape on capping tendency [L-032]
    Interaction with L-HPC and vitamins [L-038]
    Minitablets using L-HPC [L-024]
    Pellet extrusion - spheronizazion using L-HPC [L-011]
    Pellets preparation by drug layering using L-HPC [L-015]
    Rapid release from hard capsules using L-HPC as a filler [L-009]
    Roller compaction using L-HPC - influence of re-processing [L-010]
    Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
    The effect of a glidant on L-HPC [L-029]
    The effect of a glidant on L-HPC for dry granulation [L-030]
    Twin screw granulation using L-HPC [L-028]
    Water absorption of L-HPC [L-041]
    Water binding capability of L-HPC in wet granulation [L-018]
    L-HPC LH-31. 32 20 µm, 8-11 % HPONF, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Change of swelling performance of disintegrants after wet granulation [L-031]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
    Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
    Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
    Influence of tablet shape on capping tendency [L-032]
    Interaction with L-HPC and vitamins [L-038]
    Minitablets using L-HPC [L-024]
    Pellet extrusion - spheronizazion using L-HPC [L-011]
    Pellets preparation by drug layering using L-HPC [L-015]
    Rapid release from hard capsules using L-HPC as a filler [L-009]
    Roller compaction using L-HPC - influence of re-processing [L-010]
    Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
    The effect of a glidant on L-HPC [L-029]
    The effect of a glidant on L-HPC for dry granulation [L-030]
    Twin screw granulation using L-HPC [L-028]
    Water absorption of L-HPC [L-041]
    Water binding capability of L-HPC in wet granulation [L-018]
    L-HPC NBD-020 45 µm, 14 % HPONF, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
    Super-high speed direct compression using L-HPC NBD [L-027]
    L-HPC NBD-021 45 µm, 11 % HPONF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
    Super-high speed direct compression using L-HPC NBD [L-027]
    L-HPC NBD-022 45 µm, 8 % HPONF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
    Super-high speed direct compression using L-HPC NBD [L-027]

    Direct compression (DC) sustained release (SR)

    Hydrophilic matrix systems designed with water-soluble polymers, such as hypromellose (HMPC) allow more controllable and reproducible drug release by controlling the chemical and physical properties of the polymer. Typical grades used are METOLOSE® SR and TYLOPUR® SR. Both materials showing good flowability and steady batch to batch consistency are used in tablets formulations that can be transferred in a direct compression continuous manufacturing line.

    Recommended products

    GradesDescriptionPharmacopoeiaOriginRecommendationKnowledge Base
    METOLOSE® 60SH´s Hypromellose 2910, different viscosities 50-10000 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Dissolution behavior of various lower viscosity grades [P-014]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grades cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Solubility of HPMC and MC in organic solvents [M-004]
    Taste masking for fine granules by METOLOSE® and an acrylic polymer [M-003]
    METOLOSE® 65SH´s Hypromellose 2906, different viscosities 50-4000 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Dissolution behavior of various lower viscosity grades [P-014]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grades cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Solubility of HPMC and MC in organic solvents [M-004]
    Taste masking for fine granules by METOLOSE® and an acrylic polymer [M-003]
    METOLOSE® 90SH´s Hypromellose 2208, different viscosities 4000-100000 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Dissolution behavior of various lower viscosity grades [P-014]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grades cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Solubility of HPMC and MC in organic solvents [M-004]
    Taste masking for fine granules by METOLOSE® and an acrylic polymer [M-003]
    METOLOSE® SR 90SH-100SR Hypromellose 2208, 100 mPas, sustained releaseUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE SR®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A study on the robustness of the wet granulation process to prepare metformin HCL extended-release matrix tablet using METOLOSE® 90SH-15000SR [SR-006]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Coating application of METOLOSE® in extended release pellet formulation [SR-020]
    Coating application of METOLOSE® in sustained release tablets [SR-019]
    Comparative study of dissolutions from matrix tablets with METOLOSE® SR by different preparation methods [SR-012]
    Comparison between direct compression and wet granulation in hydrophilic matrix tablet using METOLOSE® SR [SR-001]
    Formulation of metformin HCl sustained release tablets [SR-018]
    Formulation of paracetamol bilayer tablet (dose: 650 mg) [SR-017]
    Impact of combination of METOLOSE®SR grades in Carbamazepine extended release matrix tablet formulation [SR-021]
    Particle size analysis of METOLOSE® SR with various laser analysers [SR-010]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Acetaminophen) [SR-014]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Metformin) [SR-011]
    QbD (Quality by Design) approach to the formulation of hydrophylic matrix tablets using METOLOSE® SR (Dipyridamole) [SR-009]
    Solvent selection in wet granulation for hydrophilic matrix tablets using METOLOSE® SR [SR-003]
    The effect of CMCNa on the dissolution profiles of hydrophylic matrix tablets containg METOLOSE® SR [SR-008]
    The effect of glidant of hydrophilic matrix tablets containing METOLOSE® SR [SR-015]
    The effect of the solubility of APIs on the dissolution profiles of hydrophylic matrix tablets containing METOLOSE® SR [SR-007]
    METOLOSE® SR 90SH-4000SR Hypromellose 2208, 4000 mPas, sustained releaseUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE SR®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A study on the robustness of the wet granulation process to prepare metformin HCL extended-release matrix tablet using METOLOSE® 90SH-15000SR [SR-006]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Coating application of METOLOSE® in extended release pellet formulation [SR-020]
    Coating application of METOLOSE® in sustained release tablets [SR-019]
    Comparative study of dissolutions from matrix tablets with METOLOSE® SR by different preparation methods [SR-012]
    Comparison between direct compression and wet granulation in hydrophilic matrix tablet using METOLOSE® SR [SR-001]
    Formulation of metformin HCl sustained release tablets [SR-018]
    Formulation of paracetamol bilayer tablet (dose: 650 mg) [SR-017]
    Impact of combination of METOLOSE®SR grades in Carbamazepine extended release matrix tablet formulation [SR-021]
    Particle size analysis of METOLOSE® SR with various laser analysers [SR-010]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Acetaminophen) [SR-014]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Metformin) [SR-011]
    QbD (Quality by Design) approach to the formulation of hydrophylic matrix tablets using METOLOSE® SR (Dipyridamole) [SR-009]
    Solvent selection in wet granulation for hydrophilic matrix tablets using METOLOSE® SR [SR-003]
    The effect of CMCNa on the dissolution profiles of hydrophylic matrix tablets containg METOLOSE® SR [SR-008]
    The effect of glidant of hydrophilic matrix tablets containing METOLOSE® SR [SR-015]
    The effect of the solubility of APIs on the dissolution profiles of hydrophylic matrix tablets containing METOLOSE® SR [SR-007]
    METOLOSE® SR 90SH-15000SR Hypromellose 2208, 15000 mPas, sustained releaseUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE SR®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A study on the robustness of the wet granulation process to prepare metformin HCL extended-release matrix tablet using METOLOSE® 90SH-15000SR [SR-006]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Coating application of METOLOSE® in extended release pellet formulation [SR-020]
    Coating application of METOLOSE® in sustained release tablets [SR-019]
    Comparative study of dissolutions from matrix tablets with METOLOSE® SR by different preparation methods [SR-012]
    Comparison between direct compression and wet granulation in hydrophilic matrix tablet using METOLOSE® SR [SR-001]
    Formulation of metformin HCl sustained release tablets [SR-018]
    Formulation of paracetamol bilayer tablet (dose: 650 mg) [SR-017]
    Impact of combination of METOLOSE®SR grades in Carbamazepine extended release matrix tablet formulation [SR-021]
    Particle size analysis of METOLOSE® SR with various laser analysers [SR-010]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Acetaminophen) [SR-014]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Metformin) [SR-011]
    QbD (Quality by Design) approach to the formulation of hydrophylic matrix tablets using METOLOSE® SR (Dipyridamole) [SR-009]
    Solvent selection in wet granulation for hydrophilic matrix tablets using METOLOSE® SR [SR-003]
    The effect of CMCNa on the dissolution profiles of hydrophylic matrix tablets containg METOLOSE® SR [SR-008]
    The effect of glidant of hydrophilic matrix tablets containing METOLOSE® SR [SR-015]
    The effect of the solubility of APIs on the dissolution profiles of hydrophylic matrix tablets containing METOLOSE® SR [SR-007]
    METOLOSE® SR 90SH-100000SR Hypromellose 2208, 100000 mPas, sustained releaseUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE SR®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A study on the robustness of the wet granulation process to prepare metformin HCL extended-release matrix tablet using METOLOSE® 90SH-15000SR [SR-006]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Coating application of METOLOSE® in extended release pellet formulation [SR-020]
    Coating application of METOLOSE® in sustained release tablets [SR-019]
    Comparative study of dissolutions from matrix tablets with METOLOSE® SR by different preparation methods [SR-012]
    Comparison between direct compression and wet granulation in hydrophilic matrix tablet using METOLOSE® SR [SR-001]
    Formulation of metformin HCl sustained release tablets [SR-018]
    Formulation of paracetamol bilayer tablet (dose: 650 mg) [SR-017]
    Impact of combination of METOLOSE®SR grades in Carbamazepine extended release matrix tablet formulation [SR-021]
    Particle size analysis of METOLOSE® SR with various laser analysers [SR-010]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Acetaminophen) [SR-014]
    QbD (Quality by Design) approach for the formulation of hydrophylic matrix tablets using METOLOSE® SR (Metformin) [SR-011]
    QbD (Quality by Design) approach to the formulation of hydrophylic matrix tablets using METOLOSE® SR (Dipyridamole) [SR-009]
    Solvent selection in wet granulation for hydrophilic matrix tablets using METOLOSE® SR [SR-003]
    The effect of CMCNa on the dissolution profiles of hydrophylic matrix tablets containg METOLOSE® SR [SR-008]
    The effect of glidant of hydrophilic matrix tablets containing METOLOSE® SR [SR-015]
    The effect of the solubility of APIs on the dissolution profiles of hydrophylic matrix tablets containing METOLOSE® SR [SR-007]
    TYLOPUR® 60SH-4000 Hypromellose 2910, 4000 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Safety Data Sheets
    Tylopur 60SH-4000
    TYLOPUR® 60SH-13000 Hypromellose 2910, 13000 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Safety Data Sheets
    Tylopur 60SH-10000
    TYLOPUR® SR 90SH-100SR Hypromellose 2208, 100 mPas, sustained releaseUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Safety Data Sheets
    Tylopur 90SH-100SR
    TYLOPUR® SR 90SH-4000SR Hypromellose 2208, 4000 mPas, sustained releaseUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Safety Data Sheets
    Tylopur 90SH-4000SR
    TYLOPUR® SR 90SH-15000SR Hypromellose 2208, 15000 mPas, sustained releaseUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Safety Data Sheets
    Tylopur 90SH-15000SR
    TYLOPUR® SR 90SH-100000SR Hypromellose 2208, 100000 mPas, sustained releaseUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Safety Data Sheets
    Tylopur 90SH-100000SR

    Enteric/delayed release coating

    Nowadays, coating machine manufacturers developed continuous coating systems allowing a higher throughput. Since the handling of tablets is minimized, damages are also reduced significantly. An enteric coating agent is used to protect drug from degradation by gastric acid or to protect gastric mucosa from irritating drugs. Thus, an enteric coating agent is insoluble in gastric juice, and it immediately dissolves when the enteric preparation transfers to the small intestine. HPMCP (hypromellose phthalate) and Shin-Etsu AQOAT® (hypromellose acetate succinate) were introduced into the market as an alternative for enteric coating.

    Recommended products

    GradesDescriptionPharmacopoeiaOriginRecommendationKnowledge Base
    HPMCP All Grades Different grades, opening >pH 5.0 - 5.5NF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    HPMCP
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of HPMCP and SmartEX® in the development of MUPS-ODT for Lansoprazol 15 mg [H-020, SE-007]
    Application of HPMCP in extended release matrix tablet formulation [H-023]
    Application of HPMCP in the development of rabeprazole sodium delayed release tablet by organic enteric coating [H-022]
    Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
    Enteric coating of hard gelatin capsules using HPMCP [H-006]
    Enteric coating of soft gelatin capsules with HPMCP [H-018]
    Film solubility of mixed HPMCP [H-011]
    HPMCP - typical coating conditions for tablets (1) [H-002]
    HPMCP - typical coating conditions for tablets (2) [H-003]
    HPMCP - typical coating conditions for tablets [H-001]
    Hydrolysis of HPMCP in ethanol-water solution [H-005]
    IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
    Itraconazole 65 mg capsule using HPMPC-50 by solid dispersion approach [H-021]
    Residual solvent in ethanol/water HPMPC-55 tablet coating [H-007]
    Solubility of HPMCP in mixed organic solvents [H-010]
    Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
    Stability of HPMCP coated tablets [H-015]
    Stability of HPMCP under humid storage conditions [H-016]
    Shin-Etsu AQOAT® AS-LF HPMCAS, 5 µm, opening pH>5.5NF, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Shin-Etsu AQOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
    Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
    Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
    Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
    Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
    Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
    Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
    Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): L-arginine partly neutralized [A-065]
    Aqueous fine particle coating with angled spray [A-044]
    Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
    Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
    Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
    Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
    Direct compression of spray dried dispersion [A-072]
    Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
    Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
    Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
    Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
    Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
    Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
    Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
    Impact of process parameters to solid dispersion particles [A-071]
    Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
    IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
    Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
    Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
    Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
    Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
    Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
    Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
    Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
    Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
    Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
    Taste masking coating for quinine tablets [A-061]
    Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
    Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
    Shin-Etsu AQOAT® AS-MF HPMCAS, 5 µm, opening pH>6.0NF, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Shin-Etsu AQOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
    Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
    Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
    Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
    Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
    Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
    Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
    Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): L-arginine partly neutralized [A-065]
    Aqueous fine particle coating with angled spray [A-044]
    Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
    Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
    Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
    Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
    Direct compression of spray dried dispersion [A-072]
    Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
    Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
    Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
    Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
    Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
    Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
    Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
    Impact of process parameters to solid dispersion particles [A-071]
    Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
    IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
    Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
    Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
    Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
    Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
    Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
    Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
    Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
    Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
    Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
    Taste masking coating for quinine tablets [A-061]
    Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
    Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
    Shin-Etsu AQOAT® AS-HF HPMCAS, 5 µm, opening pH>6.5NF, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Shin-Etsu AQOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
    Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
    Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
    Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
    Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
    Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
    Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
    Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): L-arginine partly neutralized [A-065]
    Aqueous fine particle coating with angled spray [A-044]
    Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
    Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
    Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
    Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
    Direct compression of spray dried dispersion [A-072]
    Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
    Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
    Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
    Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
    Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
    Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
    Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
    Impact of process parameters to solid dispersion particles [A-071]
    Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
    IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
    Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
    Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
    Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
    Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
    Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
    Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
    Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
    Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
    Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
    Taste masking coating for quinine tablets [A-061]
    Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
    Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
    Shin-Etsu AQOAT® AS-LG HPMCAS, 1000 µm, opening pH>5.5NF, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Shin-Etsu AQOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
    Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
    Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
    Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
    Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
    Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
    Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
    Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
    Aqueous fine particle coating with angled spray [A-044]
    Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
    Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
    Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
    Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
    Direct compression of spray dried dispersion [A-072]
    Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
    Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
    Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
    Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
    Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
    Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
    Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
    Impact of process parameters to solid dispersion particles [A-071]
    Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
    IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
    Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
    Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
    Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
    Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
    Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
    Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
    Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
    Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
    Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
    Taste masking coating for quinine tablets [A-061]
    Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
    Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
    Shin-Etsu AQOAT® AS-MG HPMCAS, 1000 µm, opening pH>6.0NF, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Shin-Etsu AQOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
    Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
    Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
    Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
    Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
    Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
    Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
    Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
    Aqueous fine particle coating with angled spray [A-044]
    Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
    Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
    Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
    Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
    Direct compression of spray dried dispersion [A-072]
    Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
    Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
    Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
    Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
    Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
    Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
    Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
    Impact of process parameters to solid dispersion particles [A-071]
    Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
    IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
    Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
    Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
    Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
    Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
    Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
    Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
    Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
    Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
    Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
    Taste masking coating for quinine tablets [A-061]
    Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
    Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
    Shin-Etsu AQOAT® AS-HG HPMCAS, 1000 µm, opening pH>6.5NF, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Shin-Etsu AQOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
    Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
    Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
    Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
    Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
    Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
    Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
    Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
    Aqueous fine particle coating with angled spray [A-044]
    Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
    Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
    Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
    Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
    Direct compression of spray dried dispersion [A-072]
    Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
    Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
    Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
    Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
    Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
    Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
    Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
    Impact of process parameters to solid dispersion particles [A-071]
    Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
    IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
    Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
    Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
    Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
    Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
    Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
    Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
    Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
    Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
    Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
    Taste masking coating for quinine tablets [A-061]
    Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
    Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]

    Tablet coating

    In the recent years, coating machine manufacturers developed continuous coating systems allowing a higher throughput. Since the handling of tablets is minimized, damages are also reduced significantly. Non-functional coatings based on low viscosity hypromellose, PHARMACOAT® or TYLOPUR® as example, can be easily applied on tablets. Compared to the batch process, a more homogenous coating layer can be achieved.

    Recommended products

    GradesDescriptionPharmacopoeiaOriginRecommendationKnowledge Base
    PHARMACOAT® 603 Hypromellose 2910, 3 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    LAB Poster Tablet defects
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    PHARMACOAT® 645 Hypromellose 2910, 4.5 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    PHARMACOAT® 606 Hypromellose 2910, 6 mPasUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    LAB Poster Tablet defects
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Solubility of PHARMACOAT® 606 in acetone/water mixtures [P-016]
    Solubility of PHARMACOAT® 606 in alcohol-water mixtures [P-004]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    PHARMACOAT® 615 Hypromellose 2910, 15 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    TYLOPUR® 603 Hypromellose 2910, 3 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 603
    TYLOPUR® 645 Hypromellose 2910, 4.5 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 645
    TYLOPUR® 605 Hypromellose 2910, 5 mPasUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 605
    TYLOPUR® 606 Hypromellose 2910, 6 mPasUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 606
    TYLOPUR® 615 Hypromellose 2910, 15 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 615

    Pellet coating

    Similar to the tablet coating, pellets can be coated by a continuous coating process. PHARMACOAT® and TYLOPUR®( low viscosity HPMCs) or METOLOSE® SM-4 (methylcellulose) are recommended for aqueous and organic film coating formulations.

    Recommended products

    GradesDescriptionPharmacopoeiaOriginRecommendationKnowledge Base
    PHARMACOAT® 603 Hypromellose 2910, 3 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    LAB Poster Tablet defects
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    PHARMACOAT® 645 Hypromellose 2910, 4.5 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    PHARMACOAT® 606 Hypromellose 2910, 6 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    LAB Poster Tablet defects
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Solubility of PHARMACOAT® 606 in acetone/water mixtures [P-016]
    Solubility of PHARMACOAT® 606 in alcohol-water mixtures [P-004]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    METOLOSE® SM-4 Methyl cellulose, 4 mPasUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    METOLOSE®
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Dissolution behavior of various lower viscosity grades [P-014]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grades cellulose derivatives [G-011]
    METOLOSE® SM-4 for pellet film coating [M-002]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Solubility of HPMC and MC in organic solvents [M-004]
    Taste masking for fine granules by METOLOSE® and an acrylic polymer [M-003]
    TYLOPUR® 603 Hypromellose 2910, 3 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 603
    TYLOPUR® 645 Hypromellose 2910, 4.5 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 645
    TYLOPUR® 605 Hypromellose 2910, 5 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 605
    TYLOPUR® 606 Hypromellose 2910, 6 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 606

    Capsule filling

    Similar to direct compression, the capsule filling process can be transferred into a continuous process as powders can be fed and continuously blended before being filled into capsules. Critical consideration points are a good powder flow and steady level of the powder bed to guaranty a homogeneous capsule filling. L-HPC (low substituted hydroxypropylcellulose) with good flow properties like LH-B1 or NBD grades can be used. L-HPC can optimize the dissolution as it absorbs water and disintegrates in a shorter time, which results in the rapid release of the drug even if the powders agglomerates in the capsule.

    Recommended products

    GradesDescriptionPharmacopoeiaOriginRecommendationKnowledge Base
    SmartEx® Plus Co-processed excipientNF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    SmartEx®Plus
    Safety Data Sheets
    Safety Data Sheet
    L-HPC LH-B1 50 µm, 11 % HPONF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
    Change of swelling performance of disintegrants after wet granulation [L-031]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
    Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
    Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
    Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
    Influence of tablet shape on capping tendency [L-032]
    Interaction with L-HPC and vitamins [L-038]
    Minitablets using L-HPC [L-024]
    Pellet extrusion - spheronizazion using L-HPC [L-011]
    Pellets preparation by drug layering using L-HPC [L-015]
    Rapid release from hard capsules using L-HPC as a filler [L-009]
    Roller compaction using L-HPC - influence of re-processing [L-010]
    Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
    The effect of a glidant on L-HPC [L-029]
    The effect of a glidant on L-HPC for dry granulation [L-030]
    Twin screw granulation using L-HPC [L-028]
    Water absorption of L-HPC [L-041]
    Water binding capability of L-HPC in wet granulation [L-018]
    L-HPC NBD-020 45 µm, 14 % HPONF, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
    Super-high speed direct compression using L-HPC NBD [L-027]
    L-HPC NBD-021 45 µm, 11 % HPONF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
    Super-high speed direct compression using L-HPC NBD [L-027]
    L-HPC NBD-022 45 µm, 8 % HPONF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    L-HPC
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
    Super-high speed direct compression using L-HPC NBD [L-027]

    Amorphous solid dispersion (ASD)

    In the field of amorphous solid dispersions, hot melt extrusion (HME) and spray drying are the most popular technology. Hot melt extrusion, being an inherent continuous unit operation benefits from carrier polymers with optimized flow properties in the feeding step as Shin-Etsu AQOAT® (HPMCAS, hypromellose acetate succinate) medium particle size grades. During the spray drying an API/polymer solution is continuously dried into a powder and collected. Thus it can be seen as a continuous system as well. Typical cellulose derivatives used are low viscosity HPMC such as PHARMACOAT® and TYLOPUR® and hypromellose ethers like HPMCP (hypromellose phthalate) or Shin-Etsu AQOAT®.

    Recommended products

    GradesDescriptionPharmacopoeiaOriginRecommendationKnowledge Base
    PHARMACOAT® 603 Hypromellose 2910, 3 mPasUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    LAB Poster Tablet defects
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    PHARMACOAT® 645 Hypromellose 2910, 4.5 mPasUSP, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    PHARMACOAT® 606 Hypromellose 2910, 6 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    LAB Poster Tablet defects
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Solubility of PHARMACOAT® 606 in acetone/water mixtures [P-016]
    Solubility of PHARMACOAT® 606 in alcohol-water mixtures [P-004]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    PHARMACOAT® 615 Hypromellose 2910, 15 mPasUSP, EP, JPJapan Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    PHARMACOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    A coating technique for high-friability tablets using PHARMACOAT® [P-011]
    An advanced coating formulation with PVA and HPMC [P-012]
    An organic coating method with PHARMACOAT®, with mixed solvent of high content of ethanol and water [P-009]
    Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
    Application of PHARMACOAT® as a carrier in solid dispersion [P-010]
    Coating formulation for logo tablets [P-013]
    Comparative study of wet granulation binders [P-017]
    Dissolution behavior of various HPMC lower viscosity grades [P-014]
    Effect of moisture content on the mechanical properties of cast HPMC films [P-005]
    Effect of plasticizers and other additives on the mechanical properties of cast HPMC films [P-008]
    Film properties of HPMC and MC [G-002]
    Film properties of low-viscosity grade cellulose derivatives [G-011]
    Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
    Taste masking coating using Shin-Etsu AQOAT® and PHARMACOAT® with controlled release [A-63, P-018]
    HPMCP All Grades Different grades, opening >pH 5.0 - 5.5NF, EP, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    HPMCP
    Pharmaceutical Excipients
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    Application of HPMCP and SmartEX® in the development of MUPS-ODT for Lansoprazol 15 mg [H-020, SE-007]
    Application of HPMCP in extended release matrix tablet formulation [H-023]
    Application of HPMCP in the development of rabeprazole sodium delayed release tablet by organic enteric coating [H-022]
    Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
    Enteric coating of hard gelatin capsules using HPMCP [H-006]
    Enteric coating of soft gelatin capsules with HPMCP [H-018]
    Film solubility of mixed HPMCP [H-011]
    HPMCP - typical coating conditions for tablets (1) [H-002]
    HPMCP - typical coating conditions for tablets (2) [H-003]
    HPMCP - typical coating conditions for tablets [H-001]
    Hydrolysis of HPMCP in ethanol-water solution [H-005]
    IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
    Itraconazole 65 mg capsule using HPMPC-50 by solid dispersion approach [H-021]
    Residual solvent in ethanol/water HPMPC-55 tablet coating [H-007]
    Solubility of HPMCP in mixed organic solvents [H-010]
    Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
    Stability of HPMCP coated tablets [H-015]
    Stability of HPMCP under humid storage conditions [H-016]
    Shin-Etsu AQOAT® AS-LMP HPMCAS, 200 µm, opening pH>5.5NF, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Shin-Etsu AQOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
    Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
    Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
    Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
    Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
    Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
    Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
    Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
    Aqueous fine particle coating with angled spray [A-044]
    Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
    Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
    Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
    Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
    Direct compression of spray dried dispersion [A-072]
    Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
    Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
    Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
    Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
    Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
    Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
    Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
    Impact of process parameters to solid dispersion particles [A-071]
    Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
    IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
    Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
    Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
    Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
    Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
    Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
    Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
    Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
    Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
    Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
    Taste masking coating for quinine tablets [A-061]
    Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
    Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
    Shin-Etsu AQOAT® AS-MMP HPMCAS, 200 µm, opening pH>6.0NF, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Shin-Etsu AQOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
    Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
    Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
    Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
    Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
    Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
    Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
    Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
    Aqueous fine particle coating with angled spray [A-044]
    Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
    Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
    Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
    Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
    Direct compression of spray dried dispersion [A-072]
    Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
    Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
    Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
    Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
    Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
    Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
    Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
    Impact of process parameters to solid dispersion particles [A-071]
    Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
    IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
    Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
    Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
    Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
    Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
    Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
    Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
    Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
    Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
    Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
    Taste masking coating for quinine tablets [A-061]
    Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
    Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
    Shin-Etsu AQOAT® AS-HMP HPMCAS, 200 µm, opening pH>6.5NF, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Shin-Etsu AQOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
    Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
    Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
    Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
    Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
    Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
    Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
    Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
    Aqueous fine particle coating with angled spray [A-044]
    Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
    Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
    Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
    Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
    Direct compression of spray dried dispersion [A-072]
    Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
    Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
    Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
    Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
    Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
    Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
    Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
    Impact of process parameters to solid dispersion particles [A-071]
    Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
    IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
    Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
    Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
    Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
    Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
    Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
    Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
    Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
    Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
    Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
    Taste masking coating for quinine tablets [A-061]
    Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
    Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
    Shin-Etsu AQOAT® AS-LG HPMCAS, 1000 µm, opening pH>5.5NF, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Shin-Etsu AQOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
    Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
    Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
    Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
    Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
    Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
    Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
    Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
    Aqueous fine particle coating with angled spray [A-044]
    Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
    Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
    Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
    Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
    Direct compression of spray dried dispersion [A-072]
    Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
    Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
    Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
    Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
    Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
    Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
    Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
    Impact of process parameters to solid dispersion particles [A-071]
    Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
    IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
    Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
    Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
    Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
    Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
    Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
    Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
    Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
    Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
    Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
    Taste masking coating for quinine tablets [A-061]
    Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
    Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
    Shin-Etsu AQOAT® AS-MG HPMCAS, 1000 µm, opening pH>6.0NF, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Shin-Etsu AQOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
    Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
    Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
    Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
    Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
    Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
    Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
    Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
    Aqueous fine particle coating with angled spray [A-044]
    Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
    Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
    Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
    Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
    Direct compression of spray dried dispersion [A-072]
    Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
    Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
    Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
    Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
    Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
    Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
    Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
    Impact of process parameters to solid dispersion particles [A-071]
    Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
    IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
    Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
    Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
    Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
    Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
    Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
    Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
    Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
    Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
    Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
    Taste masking coating for quinine tablets [A-061]
    Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
    Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
    Shin-Etsu AQOAT® AS-HG HPMCAS, 1000 µm, opening pH>6.5NF, JPJapan Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    Shin-Etsu AQOAT®
    Safety Data Sheets
    Safety Data Sheet
    Technical Information
    3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
    Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
    Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
    Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
    Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
    Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
    Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
    Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
    Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
    Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
    Aqueous fine particle coating with angled spray [A-044]
    Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
    Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
    Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
    Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
    Direct compression of spray dried dispersion [A-072]
    Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
    Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
    Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
    Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
    Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
    Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
    Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
    Impact of process parameters to solid dispersion particles [A-071]
    Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
    IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
    Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
    Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
    Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
    Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
    Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
    Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
    Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
    Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
    Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
    Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
    Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
    Taste masking coating for quinine tablets [A-061]
    Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
    Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
    TYLOPUR® 603 Hypromellose 2910, 3 mPasUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 603
    TYLOPUR® 645 Hypromellose 2910, 4.5 mPasUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 645
    TYLOPUR® 605 Hypromellose 2910, 5 mPasUSP, EP, JP, EXCiPACTGermany Very suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 605
    TYLOPUR® 606 Hypromellose 2910, 6 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 606
    TYLOPUR® 615 Hypromellose 2910, 15 mPasUSP, EP, JP, EXCiPACTGermany Suitable Select
    Related documentsLanguagesAvailable as Download or Request
    Brochures
    Guide to Applications
    Pharmaceutical Excipients
    TYLOPUR®
    Safety Data Sheets
    Tylopur 615

    Shin-Etsu’s commitment

    • High quality and high batch to batch consistency of our excipients
    • Long established manufacturer of pharmaceutical excipients
    • Production in Japan and Germany

    Get in contact

    For further technical information or advice please contact your local technical sales contact.

    Locations

     
    Tablets and Pellets

    Next area of application:

    Tablets and Pellets

    The most frequently used oral solid dosage forms.

    Read more